Scaling biologics for commercial: The importance of adopting a customer-centric approach In this blog, Bora outlines the key challenges biologics developers face on the journey towards commercialization and highlights the importance of finding a development and manufacturing partner adopting a customer-centric approach to overcome scaling issues. Scaling challenges in the dynamic biologic market...
In pharmaceutical contract manufacturing, outsourcing your product to the right Contract Development and Manufacturing Organization (CDMO) can be a daunting and concerning task. After conducting the legwork of determining the best fit for a CDMO from capabilities and organizational fit perspective, the next step is working with that vendor on determining costs. Generally speaking, there is a ton...
How can Bora Biologics help to support your next biologics project? Having a robust Cell Line Development (CLD) strategy is the foundation of biologic production that can propel a project, helping to streamline production while mitigating risk. A tailored and optimized cell line can be instrumental in overcoming development and manufacturing challenges and achieving a competitive advantage in...
The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These new therapeutic proteins are often more...